“Basic Instinct” writer Joe Eszterhas, 80, recently discussed how he plans to approach a reboot of the 1992 thriller “Basic Instinct.” 

The film writer spoke again about his plans for the project, telling Fox News Digital that being politically correct has “stripped” films of real dialogue. 

“I think that the language has been, for political reasons, the truth has been gutted in some ways,” Eszterhas told the outlet in a newly published interview. “And yes, I hope that this ‘Basic’ renewal will be as successful, language-wise, as the first one was.”

He mentioned specific lines with vulgarity, including when Stone’s co-star Michael Douglas, who played homicide detective Nick Curran, called her “the f*** of the century.”

Eszterhas said he’s glad there are conversations in the industry about political correctness. “DEI, it may be a noble concept, but it doesn’t work in drama and in film,” he added.

During an interview last month with The Wrap, Eszterhas said the film was “anti-woke” before going into detail about how the main character will be “open about her sexuality” in addition to being, “raunchy at times,” “funny,” and “iconoclastic.”

In the first film, the character Catherine Tramell, a wealthy heiress, is played by Sharon Stone.

“In terms of the woke culture, I think that there is a segment of the population that’s had it with woke culture. But then there’s also a huge segment that hasn’t. I don’t believe in woke and I don’t believe in being politically correct because I think it’s not the truth, and I like the truth spoken,” Eszterhas at the time.

He added, “The absurdities come when a woman who is sexual and open about her sexuality, you know, the culture that that I grew up in would describe that woman as a nymphomaniac. If a man did the same thing he would be a stud.”

While Eszterhas said he’d love Stone to reprise her role as Tramell, the 67-year-old actress seems less enthused about the idea.

“If it goes the way the one I was in went, I would just say, ‘I don’t know why you do it. I mean, go ahead, but good f***ing luck,” she said during a Today show appearance this week.

Stone starred in “Basic Instinct 2” in 2006, but the film was panned by both audiences and critics. It currently has a 6% critic’s score and 26% audience rating on Rotten Tomatoes.

A new experimental vaccine has been developed that appears to be successful in preventing recurrences of the deadly colorectal and pancreatic cancers.

A study led by the Jonsson Comprehensive Cancer Center at the University of California, Los Angeles, tested the ELI-002 2P vaccine on 25 patients previously treated for pancreatic and colorectal cancers.

The vaccine could “help prevent or delay cancer recurrence in high-risk patients whose tumors are driven by KRAS mutations, which are responsible for half of colorectal cancers and more than 90 percent of pancreatic cancers, researchers noted,” The Hill reported.

The patients were tested a year after the vaccine had been administered, and the average relapse-free survival times were significantly greater than historical norms.

Oncologist Dr. Thomas Marron told NewsNation the results are “extremely promising. Pancreatic cancer and colon cancer are really terrible cancers, and oftentimes even if patients can have curative-intense surgery, unfortunately this cancer tends to come back as microscopic bits of the cancer have already spread. This vaccine is really about teaching patients’ immune system how to recognize and attack those tiny amounts of cancers so that they keep them from coming back, increasing the likelihood that we can cure patients with surgery and chemotherapy or radiation.”

“Vaccines are all about teaching your immune system to recognize and attack something foreign,” he continued. “Oftentimes we catch colon cancer early because of colonoscopies and sometimes we’ll catch pancreatic cancer early enough so we can do a surgery and cut it out but small amounts remain. So the vaccine is really about teaching your immune system what in the cancer is foreign, because cancer is foreign to our body, and teaching your immune system how to hunt down and  eliminate those tiny bits that remain, and that really increases the likelihood that patients go in remission, stay in remission.”

The vaccine induced “persistent T cell responses targeting oncogenic driver KRAS mutations, alongside personalized, tumor antigen-specific T cells,” the study found, adding, “Tumor-promoting driver mutations in KRAS occur in approximately 20–25% of human tumors, including colorectal cancer (CRC) (50%) and pancreatic ductal adenocarcinoma (PDAC) (93%). Despite curative intent, relapses are common following standard locoregional therapy, particularly for resectable PDAC.”

“The long-term follow-up of the AMPLIFY-201 phase 1 study provides evidence that ELI-002 2P induces potent, polyfunctional CD4+ and CD8+ T cell immunity to mKRAS alongside frequent antigen spreading that may delay tumor recurrence,” the study stated.